Clinical Trial

Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)

Name: Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET) — clinical trial record (NCT07283575)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

Multi-center observational clinical study to evaluate the application value of ctDNA methylation monitoring in efficacy assessment and relapse prediction in patients diagnosed with recurrence or metastatic colorectal cancer receiving radiotherapy plus SOC with or without PD-1.

Trial Details

NCT Number	NCT07283575
Lead Sponsor	Fudan University
Conditions	Metastatic Colorectal Cancer ctDNA Surveillance
Enrollment	497 participants
Start Date	2025-10-10
Primary Completion	2028-10-10 (estimated)
Study Completion	2030-10-10 (estimated)
Updated on ClinicalTrials.gov	2025-12-16